What works for whom? Determining the efficacy and harm of treatments for pain

Pain

Volumn 154, Issue SUPPL. 1, 2013, Pages

  Andrew Moore, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biennial review of pain 2013; Pain; Treatment efficacy

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; CELECOXIB; CODEINE; DICLOFENAC; DULOXETINE; ETORICOXIB; GABAPENTIN; HARKOSERIDE; IBUPROFEN; MILNACIPRAN; NAPROXEN; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PREGABALIN; RIZATRIPTAN; SUMATRIPTAN; TANEZUMAB; TAPENTADOL; ZOLMITRIPTAN;

ANALGESIA; ANKYLOSING SPONDYLITIS; CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DIABETIC NEUROPATHY; DRUG EFFICACY; ECONOMIC EVALUATION; ELECTROACUPUNCTURE; EVIDENCE BASED MEDICINE; EXPECTATION; FATIGUE; FIBROMYALGIA; HEADACHE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LOW BACK PAIN; LOW LEVEL LASER THERAPY; MIGRAINE; MOOD; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PERSONAL EXPERIENCE; PHYSICAL ACTIVITY; PLACEBO EFFECT; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SHORT FORM 36; SINGLE DRUG DOSE; SLEEP; THERAPY EFFECT; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT DURATION; VISUAL ANALOG SCALE; WORK CAPACITY;

BIENNIAL REVIEW OF PAIN 2013; PAIN; TREATMENT EFFICACY;

ANALGESICS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; PAIN; PAIN MEASUREMENT; PATIENT-CENTERED CARE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888641136     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.03.024     Document Type: Conference Paper

References (80)

1. L.M. Arnold, F. Wang, J. Ahl, P.J. Gaynor, and M.M. Wohlreich Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial Arthritis Res Ther 13 2011 R86
2. N. Attal, M. Lanteri-Minet, B. Laurent, J. Fermanian, and D. Bouhassira The specific disease burden of neuropathic pain: results of a French nationwide survey PAIN® 152 2011 2836 2843
3. G. Bakland, J.T. Gran, and J.C. Nossent Increased mortality in ankylosing spondylitis is related to disease activity Ann Rheum Dis 70 2011 1921 1925
4. H.R. Barthel, J.H. Peniston, M.B. Clark, M.S. Gold, and R.D. Altman Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis Arthritis Res Ther 12 2010 R7
5. R.M. Bennett, J. Schein, M.R. Kosinski, D.J. Hewitt, D.M. Jordan, and N.R. Rosenthal Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen Arthritis Rheum 53 2005 519 527
6. A. Berger, E.M. Dukes, and G. Oster Clinical characteristics and economic costs of patients with painful neuropathic disorders J Pain 5 2004 143 149
7. J.M. Bjordal, A. Klovning, A.E. Ljunggren, and L. Slørdal Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials Eur J Pain 11 2007 125 138
8. J.M. Bjordal, M.I. Johnson, R.A. Lopes-Martins, B. Bogen, R. Chow, and A.E. Ljunggren Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials BMC Musculoskelet Disord 8 2007 51
9. D. Bouhassira, O. Chassany, J. Gaillat, T. Hanslik, O. Launay, C. Mann, C. Rabaud, O. Rogeaux, and C. Strady Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice PAIN® 153 2012 342 349
10. L.C. Chen, D.M. Ashcroft, and R.A. Elliott Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study Pharm World Sci 29 2007 661 670
11. W.H. Chung, S.I. Hung, and Y.T. Chen Genetic predisposition of life-threatening antiepileptic-induced skin reactions Expert Opin Drug Saf 9 2010 15 21
12. J. Cooke, T. Walley, and M.F. Drumond The use of health economics by hospital pharmacist decision makers - a survey of UK chief pharmacists Pharm J 259 1997 779 781
13. B. Crichton, and M. Green GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis Curr Med Res Opin 18 2002 92 96
14. C. Dahlöf, E. Loder, M. Diamond, M. Rupnow, G. Papadopoulos, and L. Mao The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials Health Qual Life Outcomes 5 2007 56
15. A.H. Doth, P.T. Hansson, M.P. Jensen, and R.S. Taylor The burden of neuropathic pain: a systematic review and meta-analysis of health utilities PAIN® 149 2010 338 344
16. M. Dougados It's good to feel better but it's better to feel good J Rheumatol 32 2005 1 2
17. R.H. Dworkin, M.P. Jensen, E. Gould, B.A. Jones, Q. Xiang, B.S. Galer, and A.R. Gammaitoni Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events J Pain 12 2011 416 424
18. R.H. Dworkin, D.C. Turk, K.W. Wyrwich, D. Beaton, C.S. Cleeland, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, R.D. Kerns, D.N. Ader, N. Brandenburg, L.B. Burke, D. Cella, J. Chandler, P. Cowan, R. Dimitrova, R. Dionne, S. Hertz, A.R. Jadad, N.P. Katz, H. Kehlet, L.D. Kramer, D.C. Manning, C. McCormick, M.P. McDermott, H.J. McQuay, S. Patel, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, D.A. Revicki, M. Rothman, K.E. Schmader, B.R. Stacey, J.W. Stauffer, T. von Stein, R.E. White, J. Witter, and S. Zavisic Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121
19. M.D. Flather, M.E. Farkouh, J.M. Pogue, and S. Yusuf Strengths and limitations of meta-analysis: larger studies may be more reliable Control Clin Trials 18 1997 568 579 discussion 661-6
20. S. Fries, T. Grosser, T.S. Price, J.A. Lawson, S. Kapoor, S. DeMarco, M.T. Pletcher, T. Wiltshire, and G.A. FitzGerald Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 Gastroenterology 130 2006 55 64
21. N.J. Goodson, A.M. Brookhart, D.P. Symmons, A.J. Silman, and D.H. Solomon Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients Ann Rheum Dis 68 2009 367 372
22. L. Gormsen, R. Rosenbergb, F.W. Bach, and T.S. Jensen Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain Eur J Pain 14 2010 127.e1 127.e8
23. J. Grimley Evans Evidence-based or evidence-biased medicine? Age Ageing 24 1995 461 463
24. A. Gülfe, L.E. Kristensen, T. Saxne, L.T. Jacobsson, I.F. Petersson, and P. Geborek Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden Arthritis Care Res (Hoboken) 62 2010 1399 1406
25. A.B. Hauber, F.R. Johnson, K.M. Grotzinger, and S. Ozdemir Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies Ann Pharmacother 44 2010 479 488
26. T. Heiberg, and T.K. Kvien Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority Arthritis Rheum 47 2002 391 397
27. D.J. Hewitt, T.W. Ho, B. Galer, M. Backonja, P. Markovitz, A. Gammaitoni, D. Michelson, J. Bolognese, A. Alon, E. Rosenberg, G. Herman, and H. Wang Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain PAIN® 152 2011 514 521
28. M. Ho, B. Lavery, and T. Pullar The risk of treatment. A study of rheumatoid arthritis patients' attitudes Br J Rheumatol 37 1998 459 460
29. D.L. Hoffman, A. Sadosky, E.M. Dukes, and J. Alvir How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? PAIN® 149 2010 194 201
30. R. Ikenberg, N. Hertel, R. Andrew Moore, M. Obradovic, G. Baxter, P. Conway, and H. Liedgens Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine J Med Econ 15 2012 724 736
31. J.I. Ivanova, H.G. Birnbaum, M. Schiller, E. Kantor, B.M. Johnstone, and R.W. Swindle Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care Spine J 11 2011 622 632
32. L.T. Jacobsson, C. Turesson, J.A. Nilsson, I.F. Petersson, E. Lindqvist, T. Saxne, and P. Geborek Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis Ann Rheum Dis 66 2007 670 675
33. S.E. Johansson, and J. Sundquist Change in lifestyle factors and their influence on health status and all-cause mortality Int J Epidemiol 28 1999 1073 1080
34. F.R. Johnson, A.B. Hauber, S. Ozdemir, and L. Lynd Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes Value Health 13 2010 418 423
35. F.R. Johnson, G. Van Houtven, S. Ozdemir, S. Hass, J. White, G. Francis, D.W. Miller, and J.T. Phillips Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy J Neurol 256 2009 554 562
36. N. Katz Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology Clin J Pain 25 2009 797 807
37. S. Kerr, G. Fairbrother, M. Crawford, M. Hogg, D. Fairbrother, and K.E. Khor Patient characteristics and quality of life among a sample of Australian chronic pain clinic attendees Intern Med J 34 2004 403 409
38. M. Kosinski, C. Janagap, K. Gajria, J. Schein, and J. Freedman Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis Curr Med Res Opin 23 2007 1615 1626
39. P. Langley, G. Müller-Schwefe, A. Nicolaou, H. Liedgens, J. Pergolizzi, and G. Varrassi The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization J Med Econ 13 2010 571 581
40. H.Y. Lin, T.T. Cheng, J.H. Wang, C.S. Lee, M.H. Chen, V. Lei, C. Lac, A.R. Gammaitoni, S.S. Smugar, and W.J. Chen Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial Int J Rheum Dis 13 2010 144 150
41. R.B. Lipton, and W.F. Stewart Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39 1999 S20 S26
42. H.J. McQuay, S. Derry, R.A. Moore, P. Poulain, and V. Legout Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain PAIN® 135 2008 217 220
43. A.A. Mangoni, R.J. Woodman, P. Gaganis, A.L. Gilbert, and K.M. Knights Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community Br J Clin Pharmacol 69 2010 689 700
44. M. Mehra, K. Hill, D. Nicholl, and J. Schadrack The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis J Med Econ 15 2012 245 252
45. M. Menken, T.L. Munsat, and J.F. Toole The global burden of disease study: implications for neurology Arch Neurol 57 2000 418 420
46. R.A. Moore, S. Derry, H.J. McQuay, and J. Paling What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs Arthritis Res Ther 10 2008 R20
47. R.A. Moore, S. Derry, H.J. McQuay, S. Straube, D. Aldington, P. Wiffen, R.F. Bell, and E. Kalso Rowbotham MC; ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences PAIN® 149 2010 173 176
48. R.A. Moore, S. Derry, H.J. McQuay, and P.J. Wiffen Single dose oral analgesics for acute postoperative pain in adults Cochrane Database Syst Rev 2011 CD008659
49. R.A. Moore, C. Eccleston, S. Derry, P. Wiffen, R.F. Bell, S. Straube, H. McQuay ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews PAIN® 150 2010 386 389
50. R.A. Moore, D. Gavaghan, M.R. Tramèr, S.L. Collins, and H.J. McQuay Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects PAIN® 78 1998 209 216
51. R.A. Moore, O.A. Moore, S. Derry, P.M. Peloso, A.R. Gammaitoni, and H. Wang Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice Ann Rheum Dis 69 2010 374 379
52. R.A. Moore, S. Straube, S. Derry, and H.J. McQuay Chronic low back pain analgesic studies - a methodological minefield PAIN® 149 2010 431 434
53. R.A. Moore, S. Straube, C. Eccleston, S. Derry, D. Aldington, P. Wiffen, R.F. Bell, K. Hamunen, C. Phillips, and H. McQuay Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses PAIN® 153 2012 265 268
54. R.A. Moore, S. Straube, J. Paine, S. Derry, and H.J. McQuay Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction PAIN® 152 2011 982 989
55. R.A. Moore, S. Straube, J. Paine, C.J. Phillips, S. Derry, and H.J. McQuay Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain PAIN® 149 2010 360 364
56. E. Nüesch, P. Dieppe, S. Reichenbach, S. Williams, S. Iff, and P. Jüni All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study BMJ 342 2011 d1165
57. E. Nüesch, S. Trelle, S. Reichenbach, A.W. Rutjes, B. Tschannen, D.G. Altman, M. Egger, and P. Jüni Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study BMJ 341 2010 c3515
58. E.M. O'Brien, R.M. Staud, A.D. Hassinger, R.C. McCulloch, J.G. Craggs, J.W. Atchison, D.D. Price, and M.E. Robinson Patient-centered perspective on treatment outcomes in chronic pain Pain Med 11 2010 6 15
59. A.S. Patel, R.D. Baker-Searle, R. Farquharson, D. Carroll, A. Moore, C.J. Phillips, R.S. Taylor, and J. Barden The impact and burden of chronic pain (CP) in the workplace: a qualitative systematic review Pain Pract 12 2012 578 589
60. K.I. Penny, A.M. Purves, B.H. Smith, W.A. Chambers, and W.C. Smith Relationship between the chronic pain grade and measures of physical, social and psychological well-being PAIN® 79 1999 275 279
61. M.N. Raftery, P. Ryan, C. Normand, A.W. Murphy, D. de la Harpe, and B.E. McGuire The economic cost of chronic noncancer pain in Ireland: results from the PRIME study, Part 2 J Pain 13 2012 139 145
62. P. Räsänen, E. Roine, H. Sintonen, V. Semberg-Konttinen, O.P. Ryynänen, and R. Roine Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review Int J Technol Assess Health Care 22 2006 235 241
63. C.G. Richardson, A. Chalmers, H.A. Llewellyn-Thomas, A. Klinkhoff, A. Carswell, and J.A. Kopec Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications J Rheumatol 34 2007 1569 1575
64. D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, and W.S. Richardson Evidence based medicine: what it is and what it isn't BMJ 312 1996 71 72
65. C. Schaefer, A. Chandran, M. Hufstader, R. Baik, M. McNett, D. Goldenberg, R. Gerwin, and G. Zlateva The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States Health Qual Life Outcomes 9 2011 71
66. J.R. Schein, M.R. Kosinski, C. Janagap-Benson, K. Gajria, P. Lin, and J.D. Freedman Functionality and health-status benefits associated with reduction of osteoarthritis pain Curr Med Res Opin 24 2008 1255 1265
67. K. Seers, and K. Friedli The patients' experiences of their chronic non-malignant pain J Adv Nurs 24 1996 1160 1168
68. B.H. Smith, A.M. Elliott, A.C. Chambers, W.C. Smith, P.C. Hannaford, and K. Penny The impact of chronic pain in the community Fam Pract 18 2001 292 299
69. T. Sokka, and T. Pincus Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care BMJ Open 1 2011 e000070
70. M.A. Sprangers, E.B. de Regt, F. Andries, H.M. van Agt, R.V. Bijl, J.B. de Boer, M. Foets, N. Hoeymans, A.E. Jacobs, G.I. Kempen, H.S. Miedema, M.A. Tijhuis, and H.C. de Haes Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 53 2000 895 907
71. B.R. Stacey, J.A. Barrett, E. Whalen, K.F. Phillips, and M.C. Rowbotham Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief J Pain 9 2008 1006 1017
72. M.R. Stafford, A. Hareendran, D.S. Ng-Mak, R.P. Insinga, R. Xu, and D.E. Stull EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs Health Qual Life Outcomes 10 2012 65
73. S. Straube, S. Derry, R.A. Moore, and H.J. McQuay Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports Rheumatology (Oxford) 49 2010 706 715
74. S. Straube, S. Derry, R.A. Moore, J. Paine, and H.J. McQuay Pregabalin in fibromyalgia - responder analysis from individual patient data BMC Musculoskelet Disord 11 2010 150
75. S. Straube, R.A. Moore, J. Paine, S. Derry, C.J. Phillips, E. Hallier, and H.J. McQuay Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response BMC Musculoskelet Disord 12 2011 125
76. N. Torrance, A.M. Elliott, A.J. Lee, and B.H. Smith Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study Eur J Pain 14 2010 380 386
77. F. Tubach, P. Ravaud, G. Baron, B. Falissard, I. Logeart, N. Bellamy, C. Bombardier, D. Felson, M. Hochberg, D. van der Heijde, and M. Dougados Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state Ann Rheum Dis 64 2005 34 37
78. R. van Seventer, M. Serpell, F.W. Bach, B. Morlion, G. Zlateva, A.G. Bushmakin, J.C. Cappelleri, and M. Nimour Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain Health Qual Life Outcomes 9 2011 17
79. C.P. Watson, L. Vernich, M. Chipman, and K. Reed Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial Neurology 51 1998 1166 1171
80. C.M. Wenig, C.O. Schmidt, T. Kohlmann, and B. Schweikert Costs of back pain in Germany Eur J Pain 13 2009 280 286